Health Canada approved Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS) who have responded…
Articles by Marisa Wexler MS
Variations in the LTAÂ gene can alter a person’s risk of developing ankylosing spondylitis (AS), a new study suggests.
Health Canada has approved Cimzia (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial…
Mabpharm has filed an application with China’s National Medical Products Administration (NMPA) seeking approval of a biobetter of…
The efficacy of TNF inhibitors in slowing disease progression in people with ankylosing spondylitis (AS) may be underestimated…
Treatment with Taltz (ixekizumab) reduces fatigue and pain in people with ankylosing spondylitis (AS) for up to…
Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to…
Treatment with the experimental therapy bimekizumab is safe and shows sustained efficacy over 48 weeks in people with…
The European Commission has approved a label update for Cosentyx (secukinumab) that will allow healthcare providers to…
Depression is more common among people with ankylosing spondylitis (AS) than in the general population, with about a…